Companies › Anbogen Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ABT-101 HER2 tyrosine kinase inhibitor | ERBB2 | Phase 1 | Advanced Solid Tumor | Nov 2026 |
| ABT-301 Histone deacetylase inhibitor (HDACi) | – | Phase 1 | Colorectal Cancer (Diagnosis) | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05532696 | ABT-101 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2026 |
| NCT07244705 | ABT-301 | Phase 1 | Colorectal Cancer (Diagnosis) | Oncology | Apr 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.